Clinical Trial Update: Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524 [Phase 1, Phase 2]

View source ↗

Summary

This open-label, dose-escalation Phase 1/2 trial evaluated 2 to 5 intramuscular doses of MEDI-524 at 3 mg/kg or 15 mg/kg in children with Respiratory Syncytial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• MEDI-524

Snippet

Sponsor: MedImmune LLC | Conditions: Respiratory Syncytial Virus Infections | Phase 1, Phase 2 | Status: COMPLETED